MarketFriction

Cipla Ltd

NSE CIPLA · BSE 500087 · Pharmaceuticals
₹1,344.00 -0.15%
NSE close2026-10-01
52 week range1,165.70 - 1,673.00
Market cap₹1,11,430 Cr.
P/E31.1
Results 27-10 Nifty 50Nifty 100Nifty 200Nifty 500Nifty PharmaNifty Healthcare Index No price band Delivery 52.7%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales6,6786,6046,1636,6947,0517,0736,7306,9577,5897,0746,5417,119
Expenses4,9444,8564,8474,9785,1655,0845,1925,1795,6955,8195,5865,927
Operating Profit1,7341,7481,3161,7161,8861,9891,5381,7781,8951,2559551,192
OPM %26%26%21%26%27%28%23%26%25%18%15%17%
Other Income176-10249160191222289259269-70148211
Interest263018181515141413141317
Depreciation290233288247272280309253297278383304
Profit before tax1,5941,4741,2591,6111,7891,9161,5041,7701,8548937071,082
Tax %28%28%26%27%27%17%19%27%27%24%22%27%
Net Profit1,1551,0689321,1751,3051,5751,2141,2921,353674543786
EPS in Rs14.0113.0811.6314.5816.1319.4515.1316.0616.738.376.879.77
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales13,79014,39415,15616,36217,13219,16021,76322,75325,77427,54828,16328,324
Expenses11,31011,89812,32913,26513,92614,90717,21117,72619,48320,42022,28023,027
Operating Profit2,4802,4962,8263,0973,2064,2524,5535,0276,2917,1285,8835,297
OPM %18%17%19%19%19%22%21%22%24%26%21%19%
Other Income20820828047734426699293552862606558
Interest20715911416819716110611090625457
Depreciation7541,3231,3231,3261,1751,0681,0521,1721,0511,1071,2111,262
Profit before tax1,7271,2221,6692,0792,1783,2903,4934,0385,7026,8215,2244,536
Tax %19%15%15%27%29%27%27%30%27%22%26%
Net Profit1,3831,0351,4171,4921,5002,3892,5472,8334,1545,2693,8623,356
EPS in Rs16.9312.5117.5218.9619.1829.8231.1934.7151.0565.2848.0241.74
Dividend Payout %12%16%17%16%21%17%16%24%25%25%27%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth7%8%7%2%
Compounded Profit Growth11%10%10%-34%
Stock Price CAGR9%7%5%-8%
Return on Equity13%14%15%12%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161161161161161161161161161161162162
Reserves10,64111,35612,38314,06814,85115,60218,16520,68023,24626,54531,03234,270
Borrowings1,7035,2024,1134,0984,3162,8162,0141,056803559438614
Other Liabilities3,1664,3314,2134,3464,4334,8434,5144,9605,0895,2675,7027,297
Total Liabilities15,67021,04920,86922,67323,76223,42324,85526,85729,30032,53337,33442,343
Fixed Assets6,8309,3689,4929,9509,6089,6839,5169,6839,1609,60710,00612,434
CWIP5812,0611,6839816768259697661,0931,1531,5662,042
Investments6407599731,2592,5541,4712,7102,5513,6625,4497,9338,223
Other Assets7,6208,8628,72110,48310,92311,44411,66113,85715,38416,32317,82819,643
Total Assets15,67021,04920,86922,67323,76223,42324,85526,85729,30032,53337,33442,343
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1,1731,7412,3821,4631,6913,0683,7553,3263,2384,1345,0053,940
Cash from Investing Activity-950-4,533-1,304-834-1,688114-2,374-1,858-2,376-2,982-3,682-2,234
Cash from Financing Activity1653,104-1,326-385-349-2,949-1,240-1,600-958-1,200-1,293-1,234
Net Cash Flow388312-248243-345234141-132-97-4930473
Free Cash Flow5486881,2847231,1872,0832,9642,6452,1022,8193,490928
CFO/OP72%91%113%77%74%122%113%98%90%91%94%94%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days646265759383665765687373
Inventory Days329273239271250267232230228217231252
Days Payable126106108142123139103108112102116123
Cash Conversion Cycle267230196204220211195180181182188202
Working Capital Days89-10991181321139495113120128106
ROCE %15%13%7%9%11%12%17%17%18%23%23%15%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters33.46%33.46%33.46%30.91%30.93%29.19%29.20%29.19%29.22%29.22%29.22%29.22%
FIIs25.74%25.73%25.82%27.82%28.80%26.65%26.28%25.24%24.54%23.93%22.55%20.20%
DIIs23.90%24.05%24.15%24.66%23.95%27.49%27.89%28.98%29.98%30.45%31.71%34.35%
Government0.21%0.21%0.21%0.21%0.21%0.23%0.26%0.27%0.27%0.27%0.27%0.28%
Public16.68%16.53%16.36%16.40%16.11%16.43%16.36%16.30%15.99%16.12%16.26%15.93%
No. of Shareholders4,26,8634,25,7314,36,1544,63,5694,70,2345,25,1145,43,4205,49,6555,34,5875,40,5215,84,2175,78,679

Fundamentals

Market Cap₹ 1,11,430 Cr.
Current Price₹ 1,379
Stock P/E31.1
Book Value₹ 426
ROCE15.5 %
ROE11.6 %
Dividend Yield0.94 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)2%
Compounded Profit Growth (TTM)-34%
Consolidated figures.
Valuation
Market capRs 108,566 Cr
Enterprise valueRs 107,872 Cr
P/E (TTM)32.21x
Price to book3.15x
Price to sales3.83x
EV / EBITDA18.42x
EV / EBIT23.49x
EV / sales3.81x
Price to cash flow27.55x
Earnings yield3.10%
Dividend yield0.97%
P/E, 3-year average25.64x
P/B, 3-year average3.71x
P/E, 5-year average27.10x
P/B, 5-year average3.64x
Profitability
Operating margin (excl. other income)20.89%
Operating margin (incl. other income)23.04%
EBITDA margin20.67%
Pre-tax margin16.01%
Net profit margin11.90%
Net margin, latest quarter11.08%
ROE11.82%
ROCE15.83%
ROA9.74%
ROE, 3-year average15.49%
ROCE, 3-year average20.57%
ROA, 3-year average12.72%
ROE, 5-year average14.40%
ROCE, 5-year average19.35%
ROA, 5-year average11.57%
ROIC (approx.)10.09%
Tax rate25.92%
Other income / net worth1.76%
Growth
Sales growth (latest year)2.23%
Profit growth (latest year)-26.43%
Sales CAGR, 3 years7.37%
Sales CAGR, 5 years8.01%
Profit CAGR, 3 years11.45%
Profit CAGR, 5 years10.04%
Sales growth QoQ8.84%
Profit growth QoQ42.26%
Sales growth YoY (latest quarter)2.33%
Profit growth YoY (latest quarter)-39.19%
Per share
EPS (TTM)Rs 41.73
EPS (latest year)Rs 48.02
EPS (latest quarter)Rs 9.77
EPS, 3-year averageRs 54.79
EPS, 5-year averageRs 46.05
Book value per shareRs 426.25
Sales per shareRs 350.64
Cash flow per shareRs 48.78
Free cash flow per shareRs 11.49
Dividend per share (latest year)Rs 13.00
Dividend per share, 3-year averageRs 14.00
Dividend per share, 5-year averageRs 11.10
Dividends
Dividend payout27.07%
Dividend payout, 3-year average25.68%
Dividend payout, 5-year average23.51%
Efficiency
Asset turnover0.67x
Fixed asset turnover2.26x
Inventory turnover1.76x
Inventory days207 days
Debtor days73 days
Debtors turnover5.01x
Creditor days123 days
Cash conversion cycle202 days
Working capital days106 days
Leverage
Total debtRs 614 Cr
Cash and bankRs 1,307 Cr
Net debtRs -694 Cr
Debt to equity0.02x
Net debt / EBITDA-0.12x
Interest coverage80.06x
Current ratio (filing 2026-03-31)3.44x
Quick ratio (filing 2026-03-31)2.50x
Trade payables (filing 2026-03-31)Rs 3,230 Cr
Owners' fund to total sources81.32%
Debt to assets1.45%
Cash flow
Cash from Operating Activity (latest year)Rs 3,940 Cr
Cash from Investing Activity (latest year)Rs -2,234 Cr
Cash from Financing Activity (latest year)Rs -1,234 Cr
Net Cash Flow (latest year)Rs 473 Cr
Free cash flow (latest year)Rs 928 Cr
FCFE (approx.: FCF + change in debt)Rs 1,104 Cr
Cash from ops / profit, 5 years1.05x
Sales to cash flow7.15x
Statement figures
Net sales (TTM)Rs 28,324 Cr
Net sales (latest year)Rs 28,163 Cr
Sales (latest quarter)Rs 7,119 Cr
Operating profit excl. other income (latest year)Rs 5,883 Cr
Operating profit (latest quarter)Rs 1,192 Cr
Other income (TTM)Rs 558 Cr
EBITDA (TTM)Rs 5,856 Cr
PBDT (TTM)Rs 5,798 Cr
Profit before tax (TTM)Rs 4,536 Cr
Tax (latest year)Rs 1,354 Cr
Net profit (TTM)Rs 3,371 Cr
Net profit (latest year)Rs 3,879 Cr
Net profit (latest quarter)Rs 789 Cr
Depreciation (TTM)Rs 1,262 Cr
Depreciation (latest quarter)Rs 304 Cr
Interest (TTM)Rs 57 Cr
Cost of goods sold (latest year)Rs 11,619 Cr
Total expenditure (latest year)Rs 22,280 Cr
Total income (latest year)Rs 28,769 Cr
Share capitalRs 162 Cr
ReservesRs 34,270 Cr
Shareholders' fundsRs 34,432 Cr
Total assetsRs 42,343 Cr
Net blockRs 12,434 Cr
Capital work in progressRs 2,042 Cr
InvestmentsRs 8,223 Cr
ReceivablesRs 5,620 Cr
InventoryRs 6,597 Cr
Other liabilitiesRs 7,297 Cr
Shares outstanding (crore)80.78
Ownership
Promoter holding29.22% (+0.03 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 32.2 is at the 48th percentile of its own 9.4-year range (median 32.4, low 19.7, high 50.4).
P/B 3.15 is at the 12th percentile (median 3.89).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodCIPLANifty 50Difference
1 week-3.9%-2.8% -1.2 pts
1 month-5.6%-6.8% +1.2 pts
3 months-7.8%-7.6% -0.2 pts
6 months+9.8%+0.4% +9.4 pts
1 year-11.0%-9.9% -1.1 pts
2 years-18.9%-13.6% -5.4 pts
3 years+13.3%+14.2% -0.9 pts
5 years+36.3%+27.9% +8.4 pts
301 mutual fund schemes hold about ₹20,345 Cr. Over three months 65 bought more and 51 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Flexi Cap Fund2.47%2,805 -4%
Parag Parikh Flexi Cap Fund1.37%2,022 +1%
ICICI Pru Value Fund1.30%782 +5%
SBI ELSS Tax Saver Fund2.11%670 +5%
HDFC Focused Fund2.37%667 -31%
Nippon India Pharma Fund6.09%577 +7%
Nippon India Large Cap Fund1.06%576 +3%
SBI Contra Fund1.14%541 +4%
Kotak Flexi Cap Fund0.88%493 +3%
Kotak Flexi Cap Fund0.88%491 +3%
ICICI Pru Healthcare Fund-5.76%403 -6%
DSP Aggressive Hybrid Fund3.17%372 -18%
Franklin India Flexi Cap Fund1.88%365 +33%
Nippon India Multi Cap Fund0.59%335 +1%
Axis Large Cap Fund1.01%319 +3%
DSP ELSS Tax Saver Fund1.89%314 +6%
SBI Balanced Advantage Fund0.72%304 +4%
ICICI Pru Balanced Advantage Fund(M0.38%289 +100%
DSP Flexi Cap Fund2.26%282 +9%
DSP Healthcare Fund7.35%282 -4%
SBI Healthcare Opp Fund4.67%271 +44%
DSP Large & Mid Cap Fund1.41%260 +5%
ICICI Pru Large Cap Fund0.32%252 +3%
ICICI Pru India Opp Fund0.62%239 +1%
Kotak Arbitrage Fund(M0.28%215 -34%

Red flags

F-score 4 of 8
explainDebt up, profit down Borrowings up 40% while net profit fell in 2026
lookAuditor change Auditor change 2026-06-25: Cipla Limited has informed the Exchange regarding Change in Auditors of the company.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2025-09-26Renu Jain jointly with Dinesh JainImmediate relativeother15,419Gift
2025-09-26Anusha Jain jointly with Dinesh JaImmediate relativeother15,419Gift
2024-08-21Anusha JainImmediate relativesell2,000Rs 0.32 CrMarket Sale
2024-08-12Anusha JainImmediate relativesell3,000Rs 0.48 CrMarket Sale
2023-09-22Priyanka MallickEmployees/Designated Employebuy200Rs 0.02 CrMarket Purchase
2023-08-10Priyanka MallickEmployees/Designated Employebuy500Rs 0.06 CrMarket Purchase
2023-08-10Jaideep MallickImmediate relativebuy150Rs 0.02 CrMarket Purchase
2023-02-21Shachi MalpaniImmediate relativeother10,000Rs 0.97 CrPledge Creation
2023-02-13Shachi MalpaniImmediate relativeother10,000Rs 1.02 CrOff Market
2023-01-03Vidya Prabhakar Rote jointly with -other1,000Rs 0.11 CrRevokation of Pledge
2022-12-23Vidya Prabhakar Rote jointly with -other1,000Rs 0.11 CrPledge Creation
2022-12-21Vidya Prabhakar Rote jointly with -buy1,000Rs 0.11 CrMarket Purchase
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹7,119 Cr +2.3% vs Jun 2025. Net profit ₹786 Cr -39.2%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-06-05Dividend - Rs 13 Per Share
2025-06-27Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share
2024-08-02Dividend - Rs 13 Per Share
2023-07-21Dividend - Rs 8.50 Per Share
2022-08-08Dividend - Rs 5 Per Share
2021-08-09 Annual General Meeting/Dividend - Rs 5 Per Share
2020-08-11 Annual General Meeting
2020-03-19 Interim Dividend - Rs 3 Per Share Special Dividend - Re 1 Per Share
2019-07-31 Annual General Meeting/Dividend - Rs 3 Per Share
2018-08-13 Annual General Meeting/Dividend- Rs 3 Per Share
2017-07-26 Annual General Meeting/Dividend - Rs 2/- Per Share
2016-09-12 Annual General Meeting/Dividend Rs 2/- Per Share
2015-08-11Annual General Meeting/Dividend - Rs 2/- Per Share
2014-08-06Annual General Meeting/Dividend Rs 2/- Per Equity Share
2013-08-06Annual General Meeting/Dividend Rs 2/- Per Equity Share
2012-08-01Annual General Meeting And Dividend - Rs.2/- Per Share
2011-08-09Annual General Meeting And Dividend Rs.2/- Per Share
2010-09-03Special Interim Dividend Re.0.80 Per Share
2010-07-23Annual General Meeting And Dividend Rs.2/- Per Share
2009-08-10Agm/Div-Rs.2/- Per Share
2008-08-12Dividend - Rs.2 Per Share
2007-08-08Agm/Div-Rs.2/- Per Sh
2006-08-18Agm/Div-Rs.2/- Per Sh
2006-04-24Bonus 3:20.4000
DateTypeWhat it says
2026-09-24ESOPAllotment of 12168 Shares.
2026-09-22Change in ManagementChange in Senior Management Personnel.
2026-09-18General UpdatesIntimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
2026-09-03Press ReleaseA press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosi...
2026-09-03General UpdatesNotice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the...
2026-08-31Press ReleaseA press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC ...
2026-08-28General UpdatesUpdate on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
2026-08-27Other RestructuringOther Restructuring
2026-08-27Concall / analyst meetSchedule of meet
2026-08-26ESOPAllotment of 5281 Shares.
2026-08-25General UpdatesUSFDA inspection at Company s manufacturing facility in Pithampur, India
2026-08-19Amalgamation/MergerReceipt of order from Honble NCLT, Mumbai Bench.
2026-08-11General UpdatesESG Ratings.
2026-08-04General UpdatesUpdate on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA
2026-07-31AllotmentAllotment of 7850 securities pursuant to ESOP/ESPS at its meeting held on July 31, 2026
2026-07-27UpdatesCipla Receives U.S. FDA Approval for Generic Advair Diskus®.
2026-07-27Concall / analyst meetTranscript
2026-07-23Concall / analyst meetLink of Recording
2026-07-23UpdatesThe Board has approved the changes in the Key Managerial Personnels (KMPs) and Officers authorised under Regulation 30(5) of the SEBI Listing Regulati...
2026-07-23UpdatesGrant Of Stock Options and Employee Stock Appreciation Rights.
2026-07-23Change in ManagementChange in management.
2026-07-23Board meeting outcomeOutcome of Board Meeting held on July 23, 2026.
2026-07-23Press ReleaseA press release dated July 23, 2026, titled Q1 FY27 Results
2026-07-23Investor PresentationInvestor Presentation
2026-07-23Board meeting outcomeCipla Limited has submitted to the Exchange, the financial results for the period ended June 30, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.61
Max pain (expiry 2026-10-27)1,390
Largest call open interest at1,400
Largest put open interest at1,340
Implied volatility, at the money22.6%
Underlying at snapshot1,344.00
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-292,451
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2020-02-06NCLATKalyan Chowdhury. VS Cipla Ltd. & Anr.
2020-01-13NCLATKalyan Chowdhury. VS Cipla Ltd. & Anr.
2019-12-17NCLATKalyan Chowdhury. VS Cipla Ltd. & Anr.
2019-11-13NCLATKalyan Chowdhury. VS Cipla Ltd. & Anr.
2019-09-30NCLATKalyan Chowdhury. VS Cipla Ltd. & Anr.
2018-01-30CESTATCIPLA LIMITED, ---VS.--- C.C.E. INDORE
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Cipla Ltd?

Cipla Ltd (CIPLA) has a market capitalisation of Rs 1,11,430 Cr. at the 2026-10-01 close.

What is the P/E ratio of Cipla Ltd?

Cipla Ltd trades at a P/E of 31.1 on trailing twelve-month profit, at the 2026-10-01 close.

What were Cipla Ltd's latest quarterly results?

In the Jun 2026 quarter, Cipla Ltd sales was Rs 7,119 Cr (+2.3% vs Jun 2025) and net profit was Rs 786 Cr.

What is the 52-week high and low of Cipla Ltd?

The 52-week high is Rs 1,673.00 and the 52-week low is Rs 1,165.70.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03